Journal
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
Volume 45, Issue 1, Pages 81-87Publisher
WILEY
DOI: 10.1111/nan.12530
Keywords
biomarkers; blood; cerebrospinal fluid; frontotemporal dementia
Categories
Funding
- Swedish Research Council
- European Research Council
- Knut and Alice Wallenberg Foundation
- Swedish State Support for Clinical Research
- UK Dementia Research Institute at UCL
- Wellcome Trust
- Dutch Medical Research Council (NWO) [733050811, 733050813]
- Bluefield Project to Cure FTD
- Alzheimer Nederland
- NIH [R01AG038791, U54NS092089]
- University of California
- Tau Consortium
- CBD Solutions
- Alzheimer's Association
- Avid
- Biogen
- Bristol Myers Squibb
- C2N Diagnostics
- Cortice Biosciences
- Eli Lilly
- Forum
- Genentech
- Roche
- TauRx
- MRC Clinician Scientist Fellowship [MR/M008525/1]
- NIHR [BRC149/NS/MH]
- MRC UK GENFI grant [MR/M023664/1]
- Bluefield Project
- Alzheimer's Research UK
- Brain Research Trust
- Wolfson Foundation
- NIHR Queen Square Dementia Biomedical Research Unit
- NIHR UCL/H Biomedical Research Centre
- Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility
- MRC [UKDRI-1003, MR/M008525/1, MR/M023664/1] Funding Source: UKRI
Ask authors/readers for more resources
Frontotemporal dementias (FTDs) are clinically, genetically and pathologically heterogeneous neurodegenerative disorders that affect the frontal and anterior temporal lobes of the brain. They are relatively common causes of young-onset dementia and usually present with behavioural disturbance (behavioural variant FTD) or language impairment (primary progressive aphasia), but there is also overlap with motor neurone disease and the atypical parkinsonian disorders, corticobasal syndrome and progressive supranuclear palsy. At post mortem, neuronal inclusions containing tau, TDP-43 or infrequently FUS protein are seen in most cases. However, a poor correlation between clinical syndrome and underlying pathology means that it is difficult to diagnose the underlying molecular basis using clinical criteria. At this point, biomarkers for the underlying pathology come into play. This paper provides a brief update on fluid biomarkers for FTDs that may be useful to dissect the underlying molecular changes in patients presenting with signs of frontal and/or temporal lobe dysfunction. The hope is that such biomarkers, together with genetics and imaging, would be useful in clinical trials of novel drug candidates directed against specific pathologies and, in the long run, helpful in clinical practice to select the most appropriate treatment at the right dose for individual patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available